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While cadaveric vertebral bodies (VB) have long 
been proposed as a suitable source of bone marrow 
(BM) for transplantation (BMT), they have rarely been 
used for this purpose. We have infused VB BM imme-
diately following whole organ (WO) transplantation to 
augment donor cell chimerism. We quantified the he-
matopoietic progenitor cell (HPC) content of VB BM as 
well as BM obtained from the iliac crests (IC) of nor-
mal allogeneic donors (ALLO) and from patients with 
malignancy undergoing autologous marrow harvest 
(AUTO). Patients undergoing WOIBM transplantation 
also had AUTO BM harvested in the event that subse-
quent lymphohematopoietic reconstitution was re-
quired. Twenty-four VB BM, 24 IC BM-ALLO, 31 IC 
AUTO, and 24 IC WO-AUTO were harvested. VB BM 
was tested 12 to 72 hr after procurement and infused 
after completion ofWO grafting. IC BM was tested and 
then used or cryopreserved immediately. HPC were 
quantified by clonal assay measuring CFU-GM, BFU-E, 
and CFU-GEMM, and by flow cytometry for CD34+ 
progenitor cells. On an average, 9 VB were processed 
during each harvest, and despite an extended process-
ing time the number of viable nucleated cells obtained 
was significantly higher than that from IC. Further-
more, by HPC content, VB BM was equivalent to IC 
BM, which is routinely used for BMT. We conclude that 
VB BM is a clinically valuable source of BM for alloge-
neic transplantation. 
Transplantation of any organ results in the migration of 
bone marrow-derived leukocytes from the donor into the 
recipient, where they have been shown to persist indefinitely 
(1-5). We have postulated that this is the seminal explana-
tion for allograft acceptance with such migration being re-
quired as the first stage in the development of donor-specific 
nonreactivity (tolerance) (1-5). This phenomenon was aug-
mented in 18 patients by infusing donor bone marrow cells at 
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the time of whole organ transplantation (6). In the first 17 
analyzable patients receiving perioperative infusion of 3 X lOs 
unmodified donor marrow cellslkg at the time of organ graft-
ing, persistent multiline age leukocyte chimerism was dem-
onstrated for up to 16 months following transplantation. 
Donor specific hyporeactivity was also demonstrable with in 
vitro testing in the majority of these recipients as early as 50 
days posttransplantation. 
Iliac crests are routinely used as a source of bone marrow 
(BM)* from living donors (7). However, for these augmenta-
tion studies, VB BM was used, as a favorable alternative 
source with the advantage of less peripheral blood contami-
nation (8, 9). In addition, excision of vertebral bodies can be 
performed rapidly allowing subsequent extraction and pro-
cessing of the marrow. This study presents a comparison of 
hematopoietic clonogenic progenitors present in VB BM ob-
tained for combined marrow and whole organ transplanta-
tion with that from iliac crest of normal allogeneic donors and 
from patients with malignancy, undergoing autologous mar-
row harvest. 
The measurement of the engraftment potential of human 
marrow has been elusive. However, surrogate markers for 
hematopoietic stem cells have been used extensively to de-
termine the suitability of bone marrow for transplantation. 
Clinical utility has been demonstrated in the measurement 
of the nucleated cell dose with optimal engraftment at levels 
of 3 x 108 nucleated marrow cellslkg of recipient body weight 
(10). Additionally, the levels of CD34 + cells (11) and that of 
the clonal hematopoietic progenitors, (CFU-GM, BFU-E, and 
CFU-GEMM), have also been used to define autologous mar-
row collections (12-15). These parameters have been used in 
this study to compare different sources of marrow in an 
attempt to ascertain their utility in clinical bone marrow 
transplantation. 
MATERIALS AND METHODS 
Study population. The thoracolumbar vertebral column (VC) was 
harvested from 24 cadaveric organ donors, yielding an average of 9 
VB per donor. The marrow obtained was subsequently infused perio-
peratively into 18 ABO-matched recipients undergoing whole organ 
transplantation. Iliac crest marrow was harvested from 79 adult 
* Abbreviations: BFU-E, burst forming unit-erythroid; BM, bone 
marrow; BMT, bone marrow transplantation; CFU-GEMM, CFU-
granulocyte, erythrocyte, megakaryocyte, macrophage; CFU-GM, 
CFU-granulocyte macrophage; HPC, hematopoietic progenitor cell; 
IC, iliac crests; PBS, phosphate-buffered saline; VB, cadaveric ver-
tebral bodies. 
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living donors for subsequent marrow transplantation. Twenty-four of 
these harvests were from normal donors for related or unrelated 
matched allogeneic marrow transplantation. Thirty-two harvests 
were from patients undergoing chemotherapy for the treatment of 
malignancy for subsequent autologous transplantation, and 24 har-
vests were from recipients of combined organ and bone marrow 
transplantation. In the latter group, the marrow was harvested and 
cryopreserved in the event that subsequent lymphohematopoietic 
reconstitution was required. Informed consent was obtained in all 
cases. These investigations were approved by the Institutional Re-
view Board for Biomedical Research of the University of Pittsburgh. 
Vertebral body bone marrow (VB BM). The method for harvesting 
and processing marrow from VB has been described previously (16). 
Briefly, thoracolumbar VB were resected en bloc and transported to 
the University of Pittsburgh Medical Center at ambient temperature 
in "harvesting" medium containing Dulbecco's modified Eagle's me-
dium (DMEM), supplemented with 2.5% human serum albumin, 
5xl03 Dlml Bacitracin, 5X104 U/ml Polymyxin, 103 U/ml heparin, 
and 2 mM HEPES buffer (Gibco, Grand Island, NY). On arrival in 
the lab, VB were divided, the cancellous bone was chipped off, and 
the cells were released by gentle agitation into a "processing" me-
dium, the constituents of which were the same as in the harvesting 
medium, with the exception of X-VIVO 10 (BioWhittaker, Walkers-
ville, MD), which was substituted for DMEM. The released bone 
marrow cells from individual VB were then pooled, filtered, centri-
fuged at 300 xg for 11 min, and placed in a "suspension" medium 
consisting of RPMI 1640, 2.5% human serum albumin, 0.5 mg/ml 
gentamicin, 10 Dlml heparin, and 2 mM HEPES buffer, and refrig-
erated until used. At 2 to 12 hr after revascularization of the organ 
graft, 3 X 108 unmodified bone marrow cellslkg were removed, centri-
fuged, and resuspended in 200 ml of "suspension" solution, which 
was infused over 20 min via a central intravenous line into a non-
conditioned recipient. BM was tested 12 to 72 hr after procurement 
for progenitor cell assays and cell surface phenotype. 
Iliac crest marrow. Marrow from the iliac crests was obtained by 
a standard technique (7). Briefly, this consisted of aspirating 10-15 
ml of marrowlkg patient body weight by multiple percutaneous punc-
tures of the iliac crest. The target for collection was 3-6X 108 nucle-
ated cellslkg recipient body weight. The aspirated marrow was then 
placed in Medium 199 (Gibco) anticoagulated with a final concentra-
tion of 10 U/ml of heparin, and it was either transfused immediately 
or cryopreserved. The marrow was tested within 2 to 6 hr after 
procurement for clOnOgenic progenitor cells and for cell surface phe-
notype. 
Nucleated cell counts. Nucleated cell counts were obtained on all 
samples using a Coulter ZM counter (Marietta, GA). In each prepa-
ration, the absolute number of cells was calculated from the product 
of the volume and the cell concentration. 
Hematopoietic progenitor assays. The techniques used for clonal 
hematopoietic progenitor assays have been previously described (17). 
Briefly, 1.5x 105 cells suspended in Iscove's methylcellulose supple-
mented with 5% serum and PHA-LCM (Stem Cell Technologies, 
Vancouver, BC), were plated in triplicate into I-ml tissue culture 
plates and incubated in humidified 5% CO2 at 37°C for 14 days. The 
plates were scored for colony-forming unit-granulocyte and macro-
phage (CFU-GM), burst forming unit-erythroid (BFU-E), and colony-
forming unit-granulocyte, erythroid, megakaryocyte, and macro-
phage (CFU-GEMM) using an inverted microscope, and the mean 
number of colonies per 105 nucleated cells was determined. Total 
CFU were defined as the sum ofCFU-GM + BFU-E + CFU-GEMM. 
Flow cytometry. The techniques used for CD34 + cell enumeration 
have been previously described (18). Briefly, whole cell preparations 
of marrow or blood were washed in PBS, centrifuged, and enumer-
ated. The samples were then incubated for 60 min at room temper-
ature with phycoerythrin (PEl-labeled monoclonal antibody cocktail: 
CD3 (T cells), CD11b (neutrophils), CD14 (monocytesl, and CD19 (B 
cells) (Becton Dickinson, San Jose, CAl. After washing (x2) with 
PBS, the samples were incubated for an additional 1 hr with fluo-
rescein isothiocyanate (FITC)-conjugated monoclonal antibodies di-
rected against human hematopoietic progenitor cells (CD34; 8G12 
[Becton] and Q-Bend-l0 [Gen Trak, Plymouth Meeting, PA]). At the 
end of this incubation, the cells were washed (x2) in the PBS, 
erythrocytes were lysed with FACS lysing solution (Becton Dickin-
son), and the cells were subsequently fixed in 1% paraformaldehyde. 
Twenty-thousand events of each sample were acquired on a FACS-
can flow cytometer (Becton Dickinson) equipped with a 15 mW, 
air-cooled, 488 nm argon-ion laser. Fluorescence data were displayed 
on a four-decade log scale and the analysis was performed with 
L YSYS II software (Becton Dickinson). Horizontal and vertical axes 
were determined by using the PE-conjugated cocktail and unstained 
U937 cells (ATCC, Rockville, MD) respectively. CD34 + cells lacking 
the phenotype of T and B cells, monocytes and neutrophils were 
defined using the preestablished quadrants. Debris was excluded by 
reference to 6-JL beads (Calibrite, Becton Dickinson). 
RESULTS 
Cell yields. The marrow graft composition in terms of the 
numbers of nucleated cells, CD34 + cells, and total CFU is 
given in Table 1 for all four marrow sources. Quantitative 
differences between vertebral body and other sources of BM 
were significant in all categories with a P value of <0.001. On 
an average, 9 VB were harvested from each cadaveric donor, 
yielding 5.7±2.0xlOlO nucleated marrow cells/donor (a mean 
of 6.3 x 109 cellslVB), which was significantly higher than 
that obtained from any other source (Table 1). The unusually 
low number of cells recovered from iliac crests of patients 
undergoing whole organ transplantation reflects their under-
lying chronic disease state, an observation made much more 
frequently in patients with end-stage renal failure requiring 
kidney transplantation. The total numbers of hematopoietic 
progenitor cells, total CFU, and CD34 + cells paralleled the 
numbers of nucleated cells. When iliac crest was used as a 
TABLE 1. Total cell yield and progenitor cell content of bone marrow obtained from different sourcesa 
Total nucleated cells 
Marrow source 
nb (XlO '0) n 
Vertebral columnc 18 5.7±2.0 12 
Iliac crest-ALLOd 24 3.2±0.9 20 
Iliac crest-AUTO" 31 3.5±1.1 21 
Iliac crest-WO recipient! 24 1.4±0.6 17 
a The results are expressed as mean ± SD. 
b Number of samples for which measurements were successful. 
C Approximately 9 vertebral bodies were obtained from each VC harvested. 
d Normal allogeneic marrow donor. 
e Autologous marrow donor. 






f Autologous harvests from recipients of whole organ allografts and donor bone marrow. 
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source of BM, identical amounts of nucleated and CD34 + 
cells were obtained from allogeneic donors as from autolo-
gous harvests in patients with malignancy (Table 1). The 
variations between the three different groups of marrow col-
lected from iliac crests were not significant. 
Hematopoietic progenitor cell assays. The concentrations 
of clonal hematopoietic progenitors are illustrated in Figure 
1. The increased concentrations for vertebral body marrow of 
CFU-GM but not BFU-E and CFU-GEMM were significant 
at PsO.05 when compared with the other three groups. The 
proportion of CD34 + cells was similarly increased for verte-
bral body marrow, 4.6:<:: 1.8%, as compared with all iliac crest 
sources, 2.0:<:: 1.2% allogeneic, 3.4:<::4.1% autologous, and 
2.8:<::1.6% whole organ recipient. This proportional increase 
together with the greater nucleated cell content accounted 
for the substantially greater content of CFU-GM, BFU-E, 
and CFU-GEMM observed in the vertebral body marrow, as 
shown in Table 2. Qualitatively, harvests from patients with 
malignancy showed the poorest content of CFU-GM, BFU-E, 
and CFU-GEMM for comparable numbers of nucleated or 
CD34 + cells. Harvests from whole organ recipients showed 
normal CFU-GM and CFU-GEMM with increased BFU-E as 
compared with normal allogeneic donors. Nevertheless, total 
progenitors were decreased because of the lower nucleated 
cell yield. 
Viability. The viability of vertebral body marrow cells at 
the time of infusion was excellent (91:<::9%), as evidenced by 
trypan blue dye exclusion. Furthermore, equivalent viability 
was also observed in marrow from VB and that from normal 
allogeneic donors, when tested in cell culture. 
DISCUSSION 
Marrow infusion as an adjunct to whole organ transplan-
tation has been observed to promote induction oftolerance in 
animal models (19,20). The recent use of perioperative mar-
row infusion at the time of whole organ grafting in man has 
been associated with the rapid establishment of chimerism 
and with in vitro evidence of decreased antidonor reactivity 
in mixed lymphocyte culture (6). Marrow obtained from the 
vertebral bodies from cadaveric donors has been utilized in 
these trials. While cadaveric vertebral bodies have long been 
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FIGURE 1. Concentration of clonal hematopoietic progenitors-CFU-
GM, BFU-E, and CFU-GEMM-per 105 nucleated marrow cells in 
marrow from four different sources: vertebral body harvests (VERT 
BODY), iliac crest harvests in normal donors (IC ALLO BM), iliac 
crest harvests in autologous donors (IC AUTO BM), and iliac crest 
harvests in organ transplant recipients CWO AUTO). The mean and 
standard deviations are illustrated. 
TABLE 2. Hematopoietic progenitor cell content of bone marrow 
obtained from different sources 
-----
Colony-fonning units (CFU)a 
Marrow source nb CFU-GM BFU-E CFU-GEMM 
(XI08 ) (XI06 ) (XI05 ) 
Vertebral columnc 15 17.6:!:11.1 39.9:!:34.0 19.1:!:19.8 
Iliac crest-ALLOd 21 7.3:!:4.4 15.6:!:9.6 7.9:!:8.3 
Iliac crest-AUTO" 27 5.3:!:7.9 8.0:!:6.7 1.2:!: 1.8 
Iliac crest-WO recipient! 19 3.6:!:2.7 8.8:!:6.0 3.2:!:3.2 
a Mean :!: SD. 
b Number of samples for which measurements were successful. 
C Approximately 9 vertebral bodies were obtained from each VC 
harvested. 
d Normal allogeneic marrow donor. 
e Autologous marrow donor. 
f Autologous harvests from recipients of whole organ allografts 
and donor bone marrow. 
tation, they have rarely been used for this purpose. Our 
experience establishes the first large scale clinical use of this 
marrow source. 
The techniques for excising VB and extracting BM have 
been described previously (9). As expected, the yields of BM 
cells obtained depend on the number and size of VB har-
vested. Lucas et al. (21) have reported an average yield of 
4X 109 cellsNB, an amount comparable to our own observa-
tions. The determination of the quantity of marrow that 
should be collected is made arbitrarily since the ultimate 
usage of each marrow collection depends largely on organ 
allocation. Since this decision is often made following organ 
harvesting, our aim has been to maximize our yields in each 
case. The determination of the quantity of marrow that 
should be infused in each recipient was made by matching 
levels that have been reported previously to achieve full 
hematopoietic reconstitution (10). The suitability of these 
criteria will have to be determined when the long-term out-
come of this experience is known. 
Defining the quality of marrow preparations for transplan-
tation is a difficult task as no clear definition of the hemato-
poietic stem cell responsible for engraftment is available in 
man. The ability to engraft lethally conditioned hosts has 
been used as a criterion to confirm the suitability of marrow 
obtained from living donors (7), with recovery of hematopoi-
esis being used as the marker for engraftment in these pa-
tients. However, recipients of combined bone marrow and 
whole organs were not subjected to cytoablative or cytoreduc-
tive conditioning regimens prior to transplantation (6), there-
fore, recovery of hematopoiesis could not be used as a valid 
marker for engraftment in these patients. Furthermore, 
given the variable levels of chimerism achieved and high 
HLA disparities between the donor and the recipient, estab-
lishment of chimerism per se, cannot be used either as proof 
of hematopoietic engraftment or as an assessment of the 
quality of the marrow infused. Assays for CFU-GM, BFU-E, 
CFU-GEMM, and CD34 + cells have been used successfully to 
define autologous marrow collections (8-11). We have used 
these assays to assess the quality of hematopoietic progeni-
tors in marrow harvests. These assays then act as surrogate 
markers for the behavior of the stem cell pool contained in 
these collections. 
By hematopoietic progenitor cell content, vertebral body 
marrow was superior to the standard sources. The quantities 
874 TRANSPLANTATION Vol. 59, No.6 
obtained exceeded standard sources with acceptable viability 
despite prolonged holding and processing times. Further-
more, the concentrations of hematopoietic progenitors in ver-
tebral body harvests exceeded standard sources, confirming 
previous observations that aspirated marrow is diluted with 
peripheral blood. Sufficient quantities of marrow were ob-
tained from VB to graft more than one recipient if a dose of 
3 X 108 nucleated cellslkg recipient body weight is used. Thus 
a single marrow collection could support multiple recipients. 
These findings indicate that vertebral body marrow is a 
clinically valuable source of marrow for transplantation. 
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